ViiV Healthcare and Axmed have reached an agreement to expand access to HIV medicines in over 50 countries. This initiative aims to improve procurement processes and enhance treatment availability for patients living with HIV.

A systematic review evaluates various HIV post-exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines. This analysis consolidates findings from clinical trials and cohort studies, aiming to enhance treatment protocols for HIV exposure.

A cross-sectional analysis from the InterCARE study highlights significant gaps in diabetes care among individuals living with HIV and hypertension in Botswana. This research underscores the need for improved healthcare strategies to address these comorbidities.

Research identifies encleistoids A-M, a series of C-ring aromatized ent-cleistanthane diterpenoids, exhibiting anti-HIV activity derived from two Phyllanthaceae species. This discovery may contribute to future therapeutic strategies against HIV.

The CDC awards approximately $750,000 to the Elizabeth Glaser Pediatric AIDS Foundation to enhance HIV care for children and reduce mother-to-child transmission. This funding is aimed at collaborating with faith-based organizations to accelerate treatment efforts.